Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Editorial ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.01131

Tumor microenvironment and resistance to current therapies

 Ahmed Lasfar1*,  Murugabaskar Balan2, Karine A. Cohen Solal1 and  Andrew Zloza3
  • 1Rutgers, The State University of New Jersey, United States
  • 2Boston Children's Hospital, Harvard Medical School, United States
  • 3Rush University Medical Center, United States

The tumor microenvironment (TME) constitutes an important component of any cancer. The histology of TME consists of a series of normal resident cells and a variety of recruited cells, which are involved in complex and dynamic interactions with cancer cells (Figure 1). These interactions, which occur via released factors or cell-to-cell contact, are fundamental in tumor-induced suppression and metastatic dissemination of cancer cells, ultimately leading to morbidity and/or mortality for the majority of cancer patients. Considerable progress has been made in understanding the mechanisms by which the TME contributes to the inhibition or promotion of cancer, enabling the emergence of a range of novel targeted therapies. In addition to stroma-targeted strategies, checkpoint inhibitor-based immunotherapy has emerged as a new treatment of choice for many advanced cancers. However, many cancer patients remain resistant to current therapies, necessitating the development of more innovative therapeutic strategies based on the identification of new targets and combining drugs that could counteract resistance. In the present issue, “Tumor microenvironment and resistance to current therapies”, authors highlight this aspect in the included articles describing innovative and impactful studies.
In this research topic, diverse facets of the TME are addressed by experts within the field. Recently, the TME has emerged as a key player in both drug efficacy and chemoresistance, impelling the development of novel therapeutic strategies. Despite constant progress in antitumor drug development, multidrug resistance (MDR) is still a major challenge for effective patient treatment. Sachs et al., describe a novel method for overcoming this problem by demonstrating, in different cancer models, the ability of new small molecules to reverse chemotherapy resistance (Sachs et al., 2019). Munoz et al., address the problem of chemoresistance of glioblastoma multiforme (GBM), a fatal malignancy of the central nervous system. They show that a microRNA-93- and microRNA-193-mediated decrease in Cyclin D offers a partially explanation for cycling quiescence in temozolomide-resistant glioblastoma. This may open up avenues for new therapeutic approaches to reverse such chemoresistance (Munoz et al., 2019). Besides chemoresistance in GBM, expansion of residual glioma cells is also a challenge in the context of chemotherapy. Work by Tsidulko et al., indicates that conventional anti-glioblastoma therapy such as temozolomide affects proteoglycan structure and composition of normal brain tissue. Proteoglycan alteration may be involved in brain extracellular matrix (ECM) deterioration and the development of residual glioma cells (Tsidulko et al., 2018).
Although immune checkpoint blockade therapy has afforded new hope for the durable treatment of many cancers, it has not provided yet substantial benefit to patients with glioblastoma. Utilizing a series of epidemiological, genome expression, and immunome databases, Ladomersky et al., demonstrate a significant association between advanced age of patients and immunosuppression in the circulation and central nervous system. Based on their findings, the authors propose that normal human aging suppresses immune surveillance and immunotherapeutic efficacy against glioma, and thus, contributes to GBM initiation and progression (Ladomersky et al., 2018).
Using a lung cancer model, Yang et al., focus their study on bronchoalveolar lavage fluid-derived exosomes, released in the TME and demonstrate their role in fueling inflammation and tumor invasiveness (Yang et al., 2018). In a gastric cancer study, Zhao et al., analyze the role of NEDD9 in cancer cell migration under hypoxia. They demonstrate that NEDD9 regulates MICAL1, which facilitates hypoxia-induced gastric cancer cell migration in a Rac1-dependent manner (Zhao et al., 2019).
In this research topic, Tuo et al., address the role of the cytoplasmic isoform of phosphoenolpyruvate carboxykinase (PCK1) in the progression of hepatocellular carcinoma (HCC). PCK1 is a rate-limiting enzyme in gluconeogenesis which occurs mainly in the liver. The authors find that the expression of PCK1 is down regulated in HCC and associated with poor outcome. In hepatoma cells, the authors demonstrate that reactive oxygen species (ROS) production and nuclear translocation of Nrf2 and thioredoxin reductase 1 (TXNRD1) are suppressed during PCK1 overexpression. Furthermore, the authors show that targeting the TXNRD1 antioxidant pathway sensitizes PCK1-knockout hepatoma cells to sorafenib treatment in vitro (Tuo et al., 2018).
The role of natural products in the modulation of the TME is likewise addressed in this research topic. Hu et al., investigate the effect of berberine (BBR) in gastric cancer (GC). BBR is a natural isoquinoline alkaloid, presumably involved in lipid metabolism and glucose homeostasis by regulating the expression of HNF4α. The authors show that BBR inhibits the proliferation, invasion, and migration of GC cell lines, and thus reduces GC tumor growth in vivo. The antitumor effect of BBR shown appears to involve the AMPK-HNF4α-WNT5A signaling pathway (Hu et al., 2018). Using scutellarin, an active flavone extracted from Erigeron breviscapus Hand.-Mazz. (EBHM), Sun et al., investigate cisplatin resistance in non-small cell lung cancer (NSCLC). The authors find that scutellarin sensitizes tumor cells to cisplatin by enhancing via downregulation of p-AKT and c-Met in autophagy and caspase-3-dependent apoptosis. They suggest that the combination of cisplatin and scutellarin may be a novel therapeutic strategy for patients with NSCLC (Sun et al., 2018).
In this research topic, the impact of DNA damage on TME is also investigated. Tirado-Hurtado et al., highlight the role of DNA Damage Inducible Transcript 4 (DDIT4) in cancer. The DDIT4 gene is expressed under stress situations, turning off the metabolic activity triggered by the mammalian target of rapamycin (mTOR). The authors propose targeting DDIT4 for the development of novel drugs that could be more specific and efficient than current mTOR inhibitors (Tirado-Hurtado et al., 2018).
Mesenchymal stem cells (MCSs) play important role in the TME (Figure 1). In this research topic, Chulpanova et al., address the use of MCSs for drug delivery in oncology. The authors focus on MSC and tumor interactions, which are crucial for cancer control. They also describe novel therapeutic strategies using MSCs and MSC-derived membrane microvesicles for cancer therapy (Chulpanova et al., 2018).
Investigation of TME continues to be a vital focus towards the elaboration of novel strategies that produce more effective treatments for localized cancers and metastases. Findings presented in this research topic have the potential to make a major impact for inspiring further cancer discoveries.

Keywords: Cancer resistance, Tumor - targeting, tumor micoenvironment, Immunotherapy, therapy resistance, Cancer cell signaling, targeted therapy

Received: 24 Jun 2019; Accepted: 10 Oct 2019.

Copyright: © 2019 Lasfar, Balan, Cohen Solal and Zloza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Ahmed Lasfar, Rutgers, The State University of New Jersey, New Brunswick, United States,